Skip to main content
  • Explore Research
  • Learn About Clinical Trials
  • Pediatric Clinical Trials
  • Clinical Trial Video Series
  • Featured Study Opportunities
  • Find a Clinical Trial
  • Clinical Trial Patient Stories
  • Get Involved
  • Research Updates
  • Resources for Professionals
  • Newsletter Archives
  • Talk to a Specialist
  • Clinical Trial Resources

Featured Study Opportunities

The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.

 

For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.

To search by state use state code:
(For e.g NY instead of New York)
To search by state use state code:
(For e.g NY instead of New York)
Clinical Trials Phases
  • Phase 2 (21)
  • Phase 3 (13)
  • Other (12)
  • Phase 1 (5)
  • Observational Study (4)
  • open label extension (3)
  • Survey (1)

Current Results: 59 entries

BOOM-IBD Clinical Trial
Phase 2
Sponsor: Boomerang Medical Inc.
Description:

Researchers in the BOOM-IBD Clinical Trial are exploring whether nerve stimulation, a therapy already approved by the FDA to treat other conditions, can be effective for treating Inflammatory Bowel Disease.

Recruiting Now »
Highlighted Study
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF VE202 IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS
Phase 2
Sponsor: Vedanta
Description:

The goal of this study is to see if VE202 can help reduce inflammation in the large intestine and restore overall gut health in patients with mild to moderate ulcerative colitis.  To study this, VE202 will be compared with a placebo.

Recruiting Now »
A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Severe Active Left-Sided Ulcerative Colitis
Phase 3
Sponsor: InDex Pharmaceuticals - Conclude Study
Description:

Primary Objective: Induction

To evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC.

Primary Objective: Maintenance

To evaluate the efficacy of cobitolimod maintenance treatment compared to placebo in inducing or maintaining clinical remission, in participants with clinical response at I-week 6 after induction treatment with cobitolimod.

Recruiting Now »
The PRECIOUS Study: Predicting Crohn’s & Colitis Outcomes in the United States
Observational Study
Sponsor: PredictImmune PRECIOUS Study
Description:

To demonstrate that PredictSURE IBD can stratify an ethnically diverse North American population into high and low risk based on the need for early and frequent treatment escalations in the high-risk cohort.

Recruiting Now »
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants with Moderately to Severely Active Ulcerative Colitis
Phase 2
Sponsor: Arena Pharmaceuticals Inc.
Description:

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).

Recruiting Now »
A single arm, open-label study to evaluate the efficacy and safety of ABBV-668
Phase 2
Sponsor: AbbVie M21-446 - ABBV-668 - UC Study
Description:

To characterize the safety and efficacy of ABBV-668 500mg by mouth (PO) twice a day (BID) as treatment in adult patients with moderately to severely active UC.

Recruiting Now »
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis: A Randomized Crossover Trial
Observational Study
Sponsor: National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
Description:

The hypothesis of this study is that the appropriate time of day of administration of oral, once-daily 5-ASA therapy in alignment with the participant’s circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels.

Recruiting Now »
Understanding Patient Decision Making in IBD-related Surgery
Other
Sponsor: Stanford Inflammatory Bowel Disease Clinic
Description:

To understand the most important priorities of IBD patients who need surgery and quantify the reasons why patients consider delaying surgery, with potential reasons including, but not limited to lack of psychosocial support, gaps in knowledge, social stigma, burden to daily life, financial reasons, concerns about fertility, and mental well-being.

Recruiting Now »
Study to Evaluate Safety, Tolerability, and Early Efficacy of Oral E-B-FAHF-2 in Subjects with Mild-to-Moderate Crohn’s Disease
Phase 1
Sponsor: Mount Sinai Hospital - Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Description:

Primary Objective: Safety and Tolerability

Secondary Objective: Efficacy

Recruiting Now »
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) (A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With...
Phase 3
Sponsor: Takeda Kepler Study
Description:

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system in adults. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after study treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.

Recruiting Now »

Pagination

  • Current page 1
  • Page 2
  • Next page ››
  • Last page Last »
If you are interested in listing your trial on the Featured Study Opportunities page, please contact [email protected]

The Featured Study Opportunities page is made possible in part by:

Browser not supported

Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:

Google Chrome

Download Chrome

Firefox

Download Firefox

Safari (macOS 10.8+ only)

Download Safari